StockNews.com Begins Coverage on CEL-SCI (NYSE:CVM)

StockNews.com started coverage on shares of CEL-SCI (NYSE:CVM) in a research note issued to investors on Friday. The firm set a “sell” rating on the stock.

CEL-SCI Stock Down 3.6%

NYSE:CVM opened at $0.22 on Friday. The company has a market cap of $18.76 million, a PE ratio of -0.46 and a beta of 0.50. CEL-SCI has a twelve month low of $0.18 and a twelve month high of $2.22. The company has a current ratio of 1.07, a quick ratio of 1.09 and a debt-to-equity ratio of 0.66. The company’s 50 day moving average is $0.25 and its two-hundred day moving average is $0.42.

Institutional Trading of CEL-SCI

A hedge fund recently raised its stake in CEL-SCI stock. MAI Capital Management raised its holdings in shares of CEL-SCI Co. (NYSE:CVM) by 229.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 526,480 shares of the company’s stock after acquiring an additional 366,880 shares during the period. MAI Capital Management owned approximately 0.63% of CEL-SCI worth $121,000 at the end of the most recent quarter. Institutional investors own 12.08% of the company’s stock.

About CEL-SCI

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.